MDxHealth announces next phase of collab with University of Oxford

Mdxhealth (MDXH) announced the next major phase of its collaboration with the University of Oxford: the initiation of Genomic Prostate Score, GPS, testing in the landmark UK ProtecT trial. This study is designed to establish GPS as the first genomic classifier supported by randomized clinical trial evidence in an Active Surveillance cohort, further validating the clinical utility of GPS in predicting prostate cancer progression and long-term treatment outcomes.